Uncategorized

The FDA cited problems with some of Zoll’s ventilators, automated external defibrillators and electrodes.

Employers are considering raising premiums and increasing other forms of cost sharing as they grapple with stubbornly rising health costs, according to a new survey from Mercer.

Joint Commission leaders break down the standards group’s new AI certification, explaining how it’s designed to work for everyone from major health systems to small rural clinics.

UniQure’s planned third-quarter submission for its Huntington’s disease gene therapy may be a harbinger of a more flexible FDA under acting commissioner Kyle Diamantas—but how long will it last? And how can companies be sure these positive decisions won’t just be reversed?

The international launch could benefit from Boston Scientific’s global footprint when the company closes its takeover of Penumbra.

The drug middlemen lobby has had a busy week. It’s the second major lawsuit the PCMA has filed against a state law reforming the PBM industry since Monday.

In this episode of Denatured, you’ll hear from Mark Lowdell, CSO & co-founder at INmuneBio Inc. and Vishwas Seshadri, CEO & director at Abeona Therapeutics. We explore how recessive dystrophic epidermolysis bullosa has become a defining case study for gene and cell therapy and what this ultra‑rare disease reveals about the future scalability of advanced

  Durante décadas, colocar un implante dental dependió en gran medida de la pericia manual del cirujano y de su capacidad para interpretar radiografías en dos dimensiones. Hoy, ese mismo procedimiento empieza mucho antes de entrar en el quirófano: en una pantalla, …

Backed by institutional investors and seasoned industry leaders, cAMPfield Therapeutics is advancing a clinical program aimed at reshaping the landscape for inflammatory bowel disease.

The takeovers depend on Moderna reaching an agreement with the German government, which risks losing investment from drugmakers over planned healthcare reforms.